Treatment of pruritus caused by cholestasis with opioid antagonists

Journal of Palliative Medicine

Volumn 8, Issue 6, 2005, Pages 1290-1294

  Jones, E Anthony ^a   Zylicz, Z ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Hospice in the Weald   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CLONIDINE; MORPHINE; NALMEFENE; NALOXONE; NALTREXONE; OPIATE AGONIST; OPIATE ANTAGONIST; TRAMADOL; TROPISETRON;

ADULT; ANOREXIA; CASE REPORT; CHOLESTASIS; CLINICAL TRIAL; COLIC; DISEASE EXACERBATION; FEMALE; HALLUCINATION; HUMAN; HYPERTENSION; INSOMNIA; MOOD DISORDER; NAUSEA; OPIOID INDUCED EMESIS; PAIN; PRURITUS; REVIEW; SIDE EFFECT; SWEAT GLAND DISEASE; TREATMENT OUTCOME; TREMOR; VISUAL ANALOG SCALE; WITHDRAWAL SYNDROME;

CHOLESTASIS; FEMALE; HUMANS; MIDDLE AGED; NARCOTIC ANTAGONISTS; PRURITUS;

EID: 29444436194     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2005.8.1290     Document Type: Review

References (26)

1. Bergasa NV, Jones EA: The pruritus of cholestasis: Potential pathogenic and therapeutic implications of opioids. Gastroenterology 1995;108:1582-1588.
2. Jones EA, Bergasa NV: The pruritus of cholestasis. Hepatology 1999;29:1003-1006.
3. Dollery C: Therapeutic Drugs, Edinburgh: Churchill Livingstone, 1991.
4. Jaffe JH, Martin WR: Opioid analgesics and antagonists. In: Gilman AG, Rull TW, Nies AS, Taylor P (eds): Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. New York: Pergamon, 1990, pp. 485-521.
5. Koenigstein H: Experimental study of itch stimuli in animals. Arch Dermatol Syph 1948;57:828-849.
6. Thomas DA, Williams GW, Iwata K, Kenshalo DR Jr, Dubner R: Effect of central administration of opioids on facial scratching in monkeys. Brain Res 1992; 585:315-317.
7. Jones EA, Neuberger J, Bergasa NV: Opiate antagonist therapy for the pruritus of cholestasis: The avoidance of opioid withdrawal-like reactions. Q J Med 2002;95:547-552.
8. Thornton JR, Losowsky MS: Opioid peptides and primary biliary cirrhosis. Br Med J 1988;297:1501-1504.
9. Bergasa NV, Ailing DW, Vergalla J, Jones EA: Cholestasis in the male rat is associated with naloxone-reversible antinociception. J Hepatol 1994;20:85-90.
10. Swain MG, Rothman RB, Xu H, Vergalla J, Bergasa NV, Jones EA: Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 1992;103:630-635.
11. Bergasa NV, Rothman RB, Vergalla J, Xu H, Swain MG, Jones EA: Central mu-opioid receptors are down-regulated in a rat model of acute cholestasis. J Hepatol 1992;15:220-224.
12. Bergasa NV, Thomas DA, Vergalla J, Turner ML, Jones EA: Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching activity. Life Sci 1993;53:1253-1257.
13. Bergasa NV, Sabol SL, Young WS III, Kleiner DE, Jones EA: Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 1995;268:G346-G354.
14. Bergasa NV, Vergalla J, Swain MG, Jones EA: Hepatic concentrations of proenkephalin-derived opioids are increased in a rat model of cholestasis. Liver 1996;16:298-302.
15. Jones EA: Trials of opiate antagonists for the pruritus of cholestasis: primary efficacy endpoints and opioid withdrawal-like reactions. J Hepatol 2002;37:863-865.
16. McCormack HM, de L'Horne DJ, Sheather S: Clinical applications of visual analogue scales: A critical review. Psychol Med 1988;18:1007-1019.
17. Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, Korenman JC, Park Y, Hoofnagle JH, Jones EA: A controlled trial of naloxone infusions for the pruritus of cholestasis. Gastroenterology 1992;102:544-549.
18. Talbot TL, Schmitt JM, Bergasa NV, Jones EA, Walker EC: Application of piezofilm technology for the quantitation of pruritus. Biomed Instrument Technol 1991;25:400-403.
19. Molenaar HAJ, Oosting J, Jones EA: Improved device for measuring scrtching activity in patients with pruritus. Med Biol Eng Comput 1998;36:220-224.
20. Bergasa NV, Ailing DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, Schmitt JM, Walker EC, Jones EA: Effects of naloxone infusions in patients with the pruritus of cholestasis: a double-blind randomised controlled trial. Ann Intern Med 1995;123:161-167.
21. Bergasa NV, Scmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, Jenkins JB, et al: Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998;27:679-684.
22. Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA: Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study. J Amer Acad Derm 1999;41:431-434.
23. Wolfhagen FHJ, Sternieri E, Hop WCJ, Vitale G, Bertolotti M, van Buuren HR: Oral naltrexone for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997;113:1264-1269.
24. Terg R, Coronel E, Sorda J, Mufioz AE, Findor J: Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002;37:717-722.
25. Jones EA, Dekker LRC: Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 2000;118:431-432.
26. Gold MS, Redmond DE, Kleber HD: Clonidine blocks acute opiate-withdrawal symptoms. Lancet 1978;ii: 599-602.